Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia
Tags: acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), cancer, chemotherapy, chronic myelogenous leukemia (CML), sarcoma
BASi Method Number SAP.1676
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
